As ADPr-containing p62 bodies are also observed in melanoma cells following IFNγ treatment—and that such ADPr/PARP14 condensation is lost upon RBN treatment—understanding how PARP14-mediated ADP-ribosylation in p62 bodies functions could open new avenues for overcoming immunotherapy resistance. Here, SQSTM1 is linked to melanoma.